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Hip fracture affects approximately 6,500 elderly aged 65 
years or older every year in Denmark (5.7 million inhabit-
ants) (Centre for Clinical Epidemiology and Biostatistics 
North 2017, Statistics Denmark 2017). Most hip fractures in 
the elderly result from falls; only 5% of hip fracture patients 
have no fall history (Parker and Johansen 2006). Falls in the 
elderly are associated with several risk factors including gait 
and balance impairment, frailty, disability, comorbid condi-
tions, and polypharmacy (Vieira et al. 2016). Polypharmacy 
is frequent in the elderly and often includes use of antico-
agulants, statins, antipsychotics, and antidepressants (Maher 
et al. 2014). The most commonly prescribed antidepressant 
drugs are selective serotonin reuptake inhibitors (SSRIs) 
(Mars et al. 2017). SSRI use is associated with an increased 
risk of falls resulting in an emergency department visit or 
hospitalization (Macri et al. 2017). SSRI use is further asso-
ciated with an increased risk of hip fracture (Souverein et 
al. 2016), which may be due to bone loss, hyponatremia, or 
hemodynamic disturbances (Bakken et al. 2013).
SSRI use may be more prevalent in hip fracture patients 
compared with the general population (Hung et al. 2017). 
However, there are a limited number of studies on this. Fur-
thermore, factors associated with SSRI use in hip fracture 
patients are not identified. One study in individuals aged 65 
years or older without hip fracture found that SSRI users were 
more likely to be women and aged 75–94 years (Marengoni et 
al. 2016). SSRI use was strongly associated with use of other 
drugs such as other psychiatric drugs, statins, antihyperten-
sives, and anticoagulants (Marengoni et al. 2016). Another 
study found an association between hypertension, dementia, 
depression, and polypharmacy and potentially inappropriate 
medication use including SSRI use in individuals aged 65 
years or older receiving health care services (Alhmoud et al. 
2015). Some of these associated factors may contribute to the 
Background and purpose — Selective serotonin reup-
take inhibitors (SSRIs) are often used in the elderly and are 
associated with adverse effects. Therefore, it is important to 
ascertain the prevalence of SSRI use in fragile and surgery-
treated hip fracture patients.
Methods — This population-based prevalence study 
included Danish hip fracture patients aged ≥ 65 years oper-
ated in 2006–2016 (n = 68,607) and matched individuals 
from the background population (n = 343,020). Using Pois-
son regression, prevalence risk ratios (PRRs) with 95% con-
fidence intervals (CIs) were estimated to compare hip frac-
ture patients with the general population, and to estimate the 
association between hip fracture patient characteristics and 
SSRI prescriptions.
Results — The prevalence of SSRI use among hip frac-
ture patients was 23% compared with 12% in the general 
population. During 2006–2016, the prevalence decreased 
from 26% to 18% among hip fracture patients and from 
13% to 10% in the general population. Factors associated 
with SSRI use in hip fracture patients were age 75–84 years 
(PRR 1.18, CI 1.13–1.23), age ≥ 85 years (PRR 1.17, CI 
1.11–1.22), female sex (PRR 1.13, CI 1.09–1.17), unmar-
ried status (PRR 1.15, CI 1.11–1.19), living in a residential 
institution (PRR 2.30, CI 2.19–2.40), Charlson comorbidity 
index (CCI) score 1–2 (PRR 1.50, CI 1.45–1.55), CCI score 
3+ (PRR 1.62, CI 1.55–1.69), and several medications.
Interpretation — The prevalence of SSRI use was high 
among hip fracture patients compared with the general popu-
lation. Our data stress the importance of continued clinical 
awareness of frailty, comorbidity, and polypharmacy of hip 
fracture patients and the potentially adverse drug effects of 
SSRI treatment.
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increased risk of hip fracture in SSRI users. However, no pre-
vious studies have investigated this.
We therefore assessed the prevalence of SSRI use in elderly 
hip fracture patients before the fracture compared with the 
prevalence of SSRI use in the general population. Further-
more, we aimed to identify factors associated with SSRI use 
in hip fracture patients before occurrence of the fracture. 
Methods
Setting and design
The study is a nationwide cohort study using prospectively 
collected data from Danish medical registries. The health care 
system in Denmark is tax-funded, and all 5.7 million citizens 
have equal access to health care services (Statistics Denmark 
2017).
Data sources
The Danish Multidisciplinary Hip Fracture Registry (Sørensen 
et al. 2009) contains detailed pre- and postoperative clinical 
data on all patients aged 65 years or older with first-time hip 
fracture admitted to any orthopedic department in Denmark 
since 2004. These data were linked to data from the Danish 
Civil Registration System (Schmidt et al. 2014). The Danish 
Civil Registration System was established in 1968 and holds 
data on date of birth, vital status, and migration on all indi-
viduals in Denmark. Every citizen has a unique civil personal 
registration number, which allows for individual-level link-
age across all Danish registries. First, data were linked to the 
Danish National Patient Registry (Schmidt et al. 2015), which 
contains data on civil personal registration number, hospital 
admission and discharge diagnosis codes, and diagnostic and 
surgical procedure codes from all Danish somatic hospitals 
since 1977. Diagnoses were coded using the International 
Classification of Diseases Eighth Revision (ICD-8) until the 
end of 1993 and Tenth Revision (ICD-10) thereafter. Further-
more, data were linked to the Danish National Database of 
Reimbursed Prescriptions (Johannesdottir et al. 2012), which 
tracks reimbursed medicine dispensing at all community phar-
macies and hospital-based outpatient pharmacies in Denmark 
since 2004. Prescription information on individuals living 
in nursing homes is included in the database as they receive 
medication from community pharmacies. The database holds 
data on civil personal registration number, Anatomical Thera-
peutic Chemical code, redemption date, item quantity, pack 
size, defined daily dose, dose form, and generic substitution 
done at pharmacy.
Study population
Hip fracture patients aged 65 years or older undergoing sur-
gical treatment for hip fracture between 1 January 2006 and 
31 December 2016 were identified in the Danish Multidisci-
plinary Hip Fracture Registry. Using the Civil Registration 
System, each hip fracture patient was frequency matched with 
up to 5 individuals from the general population on age and sex 
at the time of surgery (index date). 
Variables
Information on age and sex of all participants was obtained 
from the Danish Civil Registration System. 3 age catego-
ries were created: 65–74 years, 75–84 years, and ≥ 85 years. 
Comorbidities of all participants were identified using the 
Danish National Patient Registry. Overall comorbidity was 
summarized according to the Charlson Comorbidity Index 
(CCI) score. The CCI was categorized as low (score 0), 
medium (score 1–2), and high (score ≥ 3) comorbidity score. 
The following medications were assessed from the Danish 
National Database of Reimbursed Prescriptions: SSRIs, non-
steroid anti-inflammatory drugs (NSAIDs), corticosteroids, 
anticoagulants, statins, non-SSRI antidepressants, and anti-
psychotics. Use of each medication including SSRIs was 
defined as follows: users redeemed at least 1 prescription 
within 1 year and non-users redeemed no prescriptions within 
365 days before hip fracture surgery date (index date). Marital 
status of hip fracture patients was obtained from the Danish 
Civil Registration System. Housing, operation year, and BMI 
information of hip fracture patients were assessed from the 
Danish Multidisciplinary Hip Fracture Registry. 4 categories 
comprising housing information were created: own accom-
modation, residential institution, homeless, and unknown. 
Likewise, 5 categories based on BMI values were created: 
underweight (BMI < 18.5), normal weight (BMI ≥ 18.5 < 25), 
overweight (BMI ≥ 25 < 30), obese (BMI ≥ 30), and unknown. 
All codes defining study variables are available in Tables 1–3 
in the Supplementary data.
Statistics
The annual prevalence of SSRI prescription redemption both 
overall and stratified by generic type was calculated in both 
hip fracture patients and the general population sample. SSRI 
use in hip fracture patients was compared with SSRI use in the 
general population sample using Poisson regression analyses 
and stratifying by age, sex, CCI, and other medication use. 
The model was evaluated for effect modification by age and 
sex. Crude and adjusted prevalence risk ratios (PRR) of SSRI 
use in hip fracture patients were estimated according to patient 
characteristics using Poisson regression analysis for compari-
son. The regression analyses were adjusted for age and sex. 
All statistical analyses were performed using Stata 14 for 
Windows (Stata Corp, College Station, TX, USA).
Ethics, funding, and potential conflicts of interest
Ethical approval was not required. As this study did not 
involve contact with patients or an intervention, it was not nec-
essary to obtain permission from the Danish Scientific Ethical 
Committee. The study was approved by the Danish Data Pro-
tection Agency (record number: 1-16-02-467-15). This work 
Acta Orthopaedica 2019; 90 (x): x–x 3
was supported by the Independent Research Fund Denmark 
(grant number 6120-00034). There are no conflicts of interest 
to declare. 
Results
We identified 68,607 first-time hip fracture patients aged 65 
years or older operated between 2006 and 2016 and 343,020 
age- and sex-matched individuals from the general popula-
tion. 16,081 (23%) hip fracture patients were SSRI users com-
pared with 41,191 (12%) in the general population sample. 
Most participants were women (71%) with a median age of 
83 (64–108) years at the index date (Table 4). Overall, 62% 
of the participants had a low CCI score, 29% had a medium 
CCI score, and 8% had a high CCI score, but the proportion 
of SSRI users increased with increasing CCI score in both 
hip fracture patients and the general population sample. Use 
of other medication was common among all participants and 
NSAIDs, anticoagulants, and statins were prescribed to more 
lation sample between 2006 and 2016.
Table 6 shows the PRRs of SSRI use in hip fracture patients 
compared with SSRI use in the general population sample. 
Overall, hip fracture patients had a higher prevalence of SSRI 
use compared with the general population. When stratifying 
by age, hip fracture patients aged 65–74 years had a PRR of 
2.88 (CI 2.75–3.02), patients aged 75–84 years had a PRR of 
2.18 (CI 2.11–2.24), and patients aged 85 years or older had a 
PRR of 1.60 (CI 1.56–1.65) compared with the general popu-
lation of the same age. Male hip fracture patients were more 
than twice as likely to have SSRI treatment compared with 
the general population. The prevalence of SSRI treatment for 
female hip fracture patients was also nearly doubled compared 
with the general population. Hip fracture patients had a higher 
prevalence of SSRI use than the general population in all CCI 
groups and when stratifying on other medication use. How-
ever, the PRR was only 1.20 (CI 1.16–1.25) when stratify-
ing on non-SSRI antidepressant use and 1.19 (CI 1.14–1.25) 
when stratifying on antipsychotic use comparing hip fracture 
patients with the general population.
Table 4. Participant characteristics according to selective serotonin reuptake inhibitor (SSRI) 
use 2006–2016. Values are frequency (%)
Variable All Hip fracture patients General population
 participants SSRI users Non-users SSRI users Non-users
Total 411,627 (100) 16,081 (23) 52,526 (77) 41,191 (12) 301,829 (88)
Median age 83 (64–108) 84 (65–105) 83 (65–108) 86 (64–106) 83 (64–108)
Age     
 65–74 79,667 (19) 2,705 (20) 10,585 (80) 4,690 (7) 61,687 (93)
 75–84 157,030 (38) 6,331 (24) 19,797 (76) 14,569 (11) 116,333 (89)
 ≥ 85 174,930 (43) 7,045 (24) 22,144 (76) 21,932 (15) 123,809 (85)
Sex     
 Male 118,706 (29) 4,219 (21) 15,567 (79) 8,288 (8) 90,632 (92)
 Female 292,921 (71) 11,862 (24) 36,959 (76) 32,903 (13) 211,197 (87)
Operation year     
 2006 37,681 (9) 1,618 (26) 4,663 (74) 4,070 (13) 27,330 (87)
 2007 38,406 (9) 1,687 (26) 4,714 (74) 4,102 (13) 27,903 (87)
 2008 41,028 (10) 1,753 (26) 5,085 (74) 4,370 (13) 29,820 (87)
 2009 37,351 (9) 1,599 (26) 4,627 (74) 3,979 (13) 27,146 (87)
 2010 39,024 (10) 1,684 (26) 4,820 (74) 4,183 (13) 28,337 (87)
 2011 39,012 (9) 1,591 (24) 4,911 (76) 4,163 (13) 28,347 (87)
 2012 37,230 (9) 1,442 (23) 4,763 (77) 3,815 (12) 27,210 (88)
 2013 37,255 (9) 1,320 (21) 4,890 (79) 3,583 (12) 27,462 (88)
 2014 36,462 (9) 1,209 (20) 4,868 (80) 3,203 (11) 27,182 (89)
 2015 36,180 (9) 1,206 (20) 4,824 (80) 3,118 (10) 27,032 (90)
 2016 31,998 (8) 972 (18) 4,361 (82) 2,605 (10) 24,060 (90)
CCI score     
 Low (0) 255,954 (62) 6,470 (19) 27,979 (81) 20,459 (9) 201,046 (91)
 Medium (1–2) 121,213 (30) 6,917 (28) 17,999 (72) 15,894 (17) 80,403 (83)
 High (3+) 34,460 (8) 2,694 (29) 6,548 (71) 4,838 (19) 20,380 (81)
Other medication     
 NSAIDs 85,307 (21) 3,559 (24) 11,033 (76) 8,677 (12) 62,038 (88)
 Corticosteroids 34,400 (8) 1,884 (27) 5,214 (73) 4,224 (15) 23,078 (85)
 Anticoagulants 184,999 (45) 9,077 (27) 24,463 (73) 22,373 (15) 129,086 (85)
 Statins 111,799 (27) 4,565 (26) 13,040 (74) 11,711 (12) 82,483 (88)
 Non-SSRI anti-
    depressants 39,550 (10) 3,798 (38) 6,117 (62) 9,683 (33) 19,952 (67)
 Antipsychotics 20,579 (6) 2,683 (42) 3,669 (58) 5,123 (36) 9,104 (64)
CCI: Charlson Comorbidity Index
than 20% (Table 4). Almost half of the 
hip fracture patients lived in their own 
accommodation (31,076, 45%) whereas 
7,105 (10%) lived in a residential insti-
tution, where the proportion of SSRI 
users was larger (41%) compared with 
patients living in their own accommoda-
tion (18%). Most hip fracture patients 
were normal weight (31,635, 46), while 
17,640 (26%) were overweight or obese. 
30,404 (44%) hip fracture patients were 
missing housing data and 13,329 (19%) 
were missing BMI data (Table 5, see 
Supplementary data).
Prevalence of SSRI use
Between 2006 and 2016, the overall prev-
alence of SSRI use decreased from 26% 
to 18% in hip fracture patients and from 
13% to 10% in the general population 
sample (Table 4 and Figure). Overall, the 
prevalence of SSRI use in both popula-
tions was stable from 2006 to 2011, after 
which the prevalence decreased until the 
end of the study period. Citalopram was 
the most frequently redeemed SSRI and 
decreased from 18% to 11% in hip frac-
ture patients and from 9% to 6% in the 
general population sample during the 
study period. The overall prevalence of 
SSRI prescriptions decreased except for 
sertraline prescriptions, which increased 
from 2% to 4% in hip fracture patients 
and from 1% to 2% in the general popu-
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Table 6. Selective serotonin reuptake inhibitor (SSRI) use in hip 
fracture patients compared with SSRI use in the general population 
sample
Variable Unadjusted PRR Adjusted PRR a
  (95% CI) (95% CI)
Total 2.0 (1.9–2.0) 2.0 (1.9–2.0)
Age  
 65–74 2.9 (2.8–3.0) 2.9 (2.8–3.0)
 75–84 2.2 (2.1–2.2) 2.2 (2.1–2.2)
 ≥ 85 1.6 (1.6–1.7) 1.6 (1.6–1.7)
Sex  
 Male 2.5 (2.5–2.6) 2.5 (2.5–2.6)
 Female 1.8 (1.8–1.8) 1.8 (1.8–1.8)
CCI score  
 Low (0) 2.0 (2.0–2.1) 1.9 (1.9–2.0)
 Medium (1–2) 1.7 (1.6–1.7) 1.7 (1.7–1.8)
 High (3+) 1.5 (1.5–1.6) 1.5 (1.5–1.6)
Other medication  
 NSAIDs 2.0 (1.9–2.1) 2.0 (1.9–2.1)
 Corticosteroids 1.7 (1.6–1.8) 1.8 (1.7–1.9)
 Anticoagulants 1.8 (1.8–1.9) 1.9 (1.8–1.9)
 Statins 2.1 (2.0–2.2) 2.1 (2.0–2.2)
 Non-SSRI antidepressants 1.2 (1.1–1.2) 1.2 (1.2–1.3)
 Antipsychotics 1.2 (1.1–1.2) 1.2 (1.1–1.3)
a Adjusted for age and sex.
CCI: Charlson Comorbidity Index
Factors associated with SSRI use in hip fracture 
patients
Hip fracture patients aged 75–84 years and 85 years or more 
were more likely to receive SSRI treatment than hip fracture 
patients aged 65–74 years. In hip fracture patients, SSRI use 
was higher among women than among men. Likewise, SSRI 
use was higher among unmarried hip fracture patients than 
among married. Living in a residential institution markedly 
increased the likelihood of receiving SSRI treatment as a hip 
fracture patient. Medium CCI score and high CCI score in 
antipsychotics were more likely to receive SSRI treatment 
compared with non-users (Table 7). 
Discussion
The prevalence of SSRI use among hip fracture patients was 
approximately double the prevalence in the general popula-
tion sample during 2006 to 2016, irrespective of age, sex, and 
CCI score at index date. SSRI prevalence was higher among 
younger hip fracture patients compared with elderly patients. 
Citalopram was the most frequently prescribed SSRI in both 
hip fracture patients and the general population sample. Sev-
eral factors including age 75 years and above, female sex, 
unmarried status, living in a residential institution, comorbid-
ity, and use of other medication were associated with higher 
SSRI use among hip fracture patients.
Strengths of this study include the large nationwide study 
population, enabling us both to study the use of SSRIs in hip 
fracture patients and to compare this with use in the gen-
eral Danish population. The data originate from registries 
based on a tax-supported and uniformly organized health 
care system, reducing the risk of recall bias. SSRIs are only 
available by prescription, which ensures accurate data on the 
redemption of the medication in the study population. The 
population of Danish hip fracture patients is similar regard-
ing age and sex to the populations used in other studies on 
hip fractures in the elderly (Lawrence et al. 2002, Roche et 
al. 2005). However, the study presents some limitations. First, 
redemption of the prescribed medication does not necessar-
ily mean that patients were compliant and took the medica-
tion. However, prescription redemption is considered a good 
measure of medication intake even in the presence of mis-
classification (Schneeweiss and Avorn 2005). Furthermore, 
patients redeeming 2 prescriptions are more likely to take 
their medication and a sensitivity analysis in a previous study 
30
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Annual prevalence of selective serotonin reuptake inhibitor use in hip fracture patients 
(left panel) and in the general population (right panel), 2006–2016, overall and stratified 
by generic type.
hip fracture patients were also associated with 
increased use of SSRIs compared with low 
CCI score. Considering the individual comor-
bidities, hip fracture patients with dementia 
were twice as likely to receive SSRI treatment 
compared with hip fracture patients without 
dementia. Other comorbidities indicating 
higher probability of SSRI use among hip 
fracture patients were myocardial infarction, 
congestive heart failure, cerebrovascular dis-
ease, chronic pulmonary disease, ulcer dis-
ease, liver disease, diabetes, hemiplegia, and 
renal disease. Hip fracture patients using other 
medication such as NSAIDs, corticosteroids, 
anticoagulants, and statins had a higher prob-
ability of redeeming SSRIs compared with 
non-users of other medication. Hip fracture 
patients using non-SSRI antidepressants and 
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showed no difference between hip fracture patients redeem-
ing only 1 prescription and those redeeming 2 (Bruun et al. 
2018). Second, comorbidity information was obtained from 
the Danish National Patient Registry, which holds only data 
on patients treated in the hospital sector. Hence, hip fracture 
patients may be more likely to have registered comorbidities 
because they are admitted to hospital. This may lead to either 
non-differential misclassification or residual confounding. 
Third, the comorbidity information did not include data on 
psychiatric diagnoses. However, we included other medica-
tion such as NSAIDs, corticosteroids, anticoagulants, statins, 
non-SSRI antidepressants, and antipsychotics, which may 
help to estimate the association between psychiatric diagno-
ses and diagnoses treated in general practice only and SSRI 
use in hip fracture patients. Fourth, we did not have informa-
tion on smoking or alcohol use, which may be risk factors for 
several comorbidities and SSRI use. However, Souverein et 
al. (2016) found that additional adjustment for these variables 
had limited impact on effect estimates examining the associa-
tion between SSRI use and the risk of hip fracture. The CCI 
included chronic obstructive pulmonary disease, which may 
function as a surrogate measure of smoking. Fifth, housing 
and BMI data were incomplete, but previous studies using 
multiple imputation of BMI on hip fracture data showed no 
impact on the estimates after adjustment for BMI (Pedersen 
et al. 2017).
Overall, the prevalence of SSRI use was doubled in hip 
fracture patients compared with the general population 
sample. A study conducted in the UK reported a prevalence of 
SSRI use of 6% in hip fracture patients and 3% in the general 
population (Hubbard et al. 2003). However, the study was 
conducted between 1987 and 1999, when SSRIs were gener-
ally less used (Mars et al. 2017). Nonetheless, the prevalence 
ratio between hip fracture patients and the general population 
is similar to our results. The decrease in prevalence between 
2006 and 2016 was reflected in both hip fracture patients 
and the general population sample. The observed decrease in 
SSRI prescribing among hip fracture patients aged 65 years 
and older may be explained by an increased clinical aware-
ness of the adverse effects related to SSRIs, which have been 
subject to debate during recent years (Topiwala et al. 2014). 
Our finding that citalopram was the most frequent subtype of 
prescribed SSRIs is consistent with results obtained from the 
general UK population (Lockhart and Guthrie 2011, McCrea 
et al. 2016).
The prevalence of SSRI use increased with increasing age 
and CCI score, and women had a higher prevalence of SSRI 
use than men in both hip fracture patients and the general 
population sample. However, when comparing hip fracture 
patients with the general population sample the relative prev-
alence increases with decreasing age and CCI score and is 
larger in men than in women. This indicates that SSRI use 
may be more prevalent in male hip fracture patients aged 
65–74 years with low CCI score than in female hip fracture 
patients aged 85 years or older with high CCI score. Bakken 
et al. (2013) found a more pronounced excess risk of hip 
fracture among men exposed to SSRIs than among exposed 
Table 7. Prevalence risk ratios (PRRs) of selective serotonin reup-
take inhibitor (SSRI) use according to hip fracture patients’ charac-
teristics
Variable Unadjusted PRR Adjusted PRR a
  (95% CI) (95% CI)
Age  
 65–74 1.0 1.0
 75–84 1.2 (1.1–1.3) 1.2 (1.1–1.2)
 ≥ 85 1.2 (1.1–1.2) 1.2 (1.1–1.2)
Sex  
 Male 1.0 1.0
 Female 1.1 (1.1–1.2) 1.1 (1.1–1.2)
Marital status  
 Married 1.0 1.0
 Unmarried 1.2 (1.2–1.2) 1.2 (1.1–1.2)
Housing  
 Own accommodation 1.0 1.0
 Homeless 0.5 (0.1–2.0) 0.5 (0.1–2.1)
 Residential institution 2.3 (2.2–2.4) 2.3 (2.2–2.4)
Operation year  
 2006 1.0 1.0
 2007 1.0 (1.0–1.1) 1.0 (1.0–1.1)
 2008 1.0 (0.9–1.1) 1.0 (0.9–1.1)
 2009 1.0 (0.9–1.1) 1.0 (0.9–1.1)
 2010 1.0 (0.9–1.1) 1.0 (0.9–1.1)
 2011 1.0 (0.9–1.0) 1.0 (0.9–1.0)
 2012 0.9 (0.8–1.0) 0.9 (0.8–1.0)
 2013 0.8 (0.8–0.9) 0.8 (0.8–0.9)
 2014 0.8 (0.7–0.8) 0.8 (0.7–0.8)
 2015 0.8 (0.7–0.8) 0.8 (0.7–0.8)
 2016 0.7 (0.7–0.8) 0.7 (0.7–0.8)
Body mass index  
 < 18.5: Underweight 1.1 (1.0–1.1) 1.0 (1.0–1.1)
 ≥ 18.5 < 25: Normal weight 1.0 1.0
 ≥ 25: Overweight or obese 1.0 (1.0–1.0) 1.0 (1.0–1.1)
Charlson comorbidity index  
 Low (0) 1.0 1.0
 Medium (1–2) 1.5 (1.4–1.5) 1.5 (1.5–1.6)
 High (3+) 1.6 (1.5–1.6) 1.6 (1.6–1.7)
Comorbidity  
 Myocardial infarction 1.1 (1.0–1.2) 1.1 (1.0–1.2)
 Congestive heart failure 1.1 (1 .1–1.2) 1.1 (1.1–1.2)
 Peripheral vascular disease 1.1 (1.1–1.2) 1.2 (1.1–1.2)
 Cerebrovascular disease 1.6 (1.5–1.6) 1.6 (1.5–1.7)
 Dementia 2.0 (1.9–2.1) 2.0 (1.9–2.1)
 Chronic pulmonary disease 1.3 (1.2–1.3) 1.3 (1.2–1.3)
 Connective tissue disease 1.0 (0.9–1.1) 1.0 (0.9–1.1)
 Ulcer disease 1.3 (1.3–1.4) 1.3 (1.3–1.4)
 Liver disease 1.1 (1.0–1.3) 1.2 (1.0–1.3)
 Diabetes type 1 and 2 1.1 (1.0–1.1) 1.1 (1.1–1.2)
 Hemiplegia 1.6 (1.2–2.0) 1.6 (1.3–2.1)
 Moderate to severe renal disease 1.1 (1.1–1.2) 1.2 (1.1–1.3)
 Cancer 1.0 (1.0–1.1) 1.0 (1.0–1.1)
Other medication  
 NSAIDs 1.1 (1.0–1.1) 1.1 (1.0–1.1)
 Corticosteroids 1.2 (1.1–1.2) 1.2 (1.1–1.2)
 Anticoagulants 1.4 (1.3–1.4) 1.4 (1.3–1.4)
 Statins 1.2 (1.1–1.2) 1.2 (1.1–1.2)
 Non-SSRI antidepressants 1.8 (1.8–1.9) 1.8 (1.8–1.9)
 Antipsychotics 2.0 (1.9–2.0) 1.0 (1.9–2.1)
a Adjusted for age and sex.
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women. This indicates that exposure to SSRIs may affect the 
risk of hip fracture relatively more in men than in women. 
Our results support this finding as the relative prevalence of 
SSRI use in hip fracture patients compared with the general 
population is higher in men than in women. A Swedish study 
found that high serum serotonin and SSRI use predicts a lower 
bone mineral density and an increased risk of hip fracture in 
elderly men (Kristjansdottir et al. 2018). This may explain 
the higher proportion of male SSRI users among elderly hip 
fracture patients compared with the general population. A 
study by Zhou et al. (2018) further supports this as it shows 
no difference between female SSRI users and non-users 
when comparing bone mineral density values. However, fur-
ther investigations are needed to assess whether the effect of 
SSRIs is more pronounced in men than in women. Our results 
further suggest that the younger age group and lower CCI 
score group of hip fracture patients have a relatively higher 
prevalence of SSRI use than the older age group and higher 
CCI score group. Nevertheless, there may be a risk of bias 
as we only had data on comorbidities treated in the hospital. 
Hip fracture patients may be more likely to have these comor-
bidities registered as they were admitted to hospital than the 
general population sample.
An Italian study investigated factors associated with SSRI 
use among the elderly aged 65 years or older. The study 
found an association between SSRI use and female sex, age 
75–94 years, and other medication such as psychiatric drugs, 
statins, and antihypertensives (Marengoni et al. 2016), which 
is similar to our findings in hip fracture patients. However, 
we also found an association with unmarried status, living in 
a residential institution, and several comorbidities. These life-
style factors and conditions suggests that hip fracture patients 
receiving SSRI treatment are more fragile than non-users. We 
expect any potential bias to be non-differential as we do not 
expect registration of the associated factors to differ between 
hip fracture patients using SSRIs and non-users. Our results 
suggest that hip fracture patients using SSRIs may have 
a more complicated course of treatment than hip fracture 
patients not treated with SSRIs. Though several factors were 
associated with SSRI use among elderly hip fracture patients, 
further studies are needed in order to uncover whether these 
patients are more prone to complications after surgery.
In summary, this nationwide cohort study based on prospec-
tively collected data from population-based Danish registries 
found a high prevalence of SSRI use of almost one-quarter 
among elderly hip fracture patients versus one-tenth in the 
general population sample. Factors associated with SSRI 
use in hip fracture patients were age 75 years and above, 
female sex, unmarried status, living in a residential institu-
tion, CCI score 1–2 and ≥ 3, and use of other medication. Our 
data stress the importance of continued clinical awareness of 
frailty among hip fracture patients and potentially monitoring 
any evidence of adverse drug effects of SSRI treatment.
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Table 1. International Classification of Diseases 10th revision (ICD-10) diagnosis codes from the Danish National Patient Registry
Disease  ICD-10 diagnosis codes
Myocardial infarction  I21; I22; I23 
Congestive heart failure  I50; I11.0; I13.0; I13.2 
Peripheral vascular disease  I70; I71; I72; I73; I74; I77 
Cerebrovascular disease  I60–I69; G45; G46 
Dementia  F00–F03; F05.1; G30 
Chronic pulmonary disease  J40–J47; J60–J67; J68.4; J70.1; J70.3; J84.1; J92.0; J96.1; J98.2; J98.3 
Connective tissue disease  M05; M06; M08; M09; M30; M31; M32; M33; M34; M35; M36; D86 
Ulcer disease  K22.1; K25–K28 
Liver disease  B18; K70.0–K70.3; K70.9; K71; K73; K74; K76.0; B15.0; B16.0; B16.2; B19.0; K70.4; K72; K76.6; I85
Diabetes type 1 and type 2  E10.0, E10.1; E10.9; E11.0; E11.1; E11.9; E10.2–E10.8; E11.2–E11.8
Hemiplegia  G81; G82 
Moderate to severe renal disease  I12; I13; N00–N05; N07; N11; N14; N17–N19; Q61 
Cancer  C00–C75; C91–C95; C81–C85; C88; C90; C96; C76–C80
Table 2. Codes from the Danish Multidisciplinary Hip Fracture Reg-
istry
Description Codes
Housing 
 Procedure code specifying housing ZZ8050
 Own accommodation ZRSB01 
 Own accommodation in association 
       with an institution  ZRSB01A 
 Homeless ZRSB02 
 Residential institution  ZRSB04 
 No information on housing ZRSB09 
Body mass index 
 Procedure code determining BMI ZZ0242
 BMI 10–80  VPH0010–VPH0080, 
  VPK10K00–VPK80K00 
Table 3. Anatomical therapeutic chemical (ATC) codes from the 
Danish National Database of Reimbursed Prescriptions
Medication ATC codes
SSRI
 Citalopram N06AB04
 Escitalopram N06AB10
 Fluoxetine N06AB03
 Fluvoxamine N06AB08
 Paroxetine N06AB05
 Sertraline N06AB06
Other medication 
 Non-SSRI antidepressants N06AA, N06AF, N06AG, N06AX
 Antipsychotics N05A
 Antithrombotic medicine B01A
 Non-steroidal anti-
     inflammatory drugs M01A
 Corticosteroids H02AB
 Statins C10AA
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Table 5. Hip fracture patient characteristics according to selective serotonin reuptake 
inhibitor (SSRI) use 2006–2016. Values are frequency (%)
Variable Total SSRI users Non-users 
Total 68,607 (100) 16,081 (23) 52,526 (77)
Marital status   
 Married 20,341 (30) 4,205 (21) 16,136 (79)
 Unmarried 48,266 (70) 11,876 (25) 36,390 (75)
Housing   
 Own accommodation 31,076 (45) 5,538 (18) 25,538 (82)
 Homeless 22 (< 1) 2 (9) 20 (91)
 Residential institution 7,105 (10) 2,892 (41) 4,213 (59)
 Unknown 30,404 (44) 7,649 (25) 22,755 (75)
Body mass index   
 < 18.5: Underweight 6,003 (9) 1,433 (24) 4,570 (76)
 ≥ 18.5 < 25: Normal weight 31,635 (46) 7,206 (23) 24,429 (77)
 ≥ 25: Overweight or obese 17,640 (26) 4,023 (23) 13,617 (77)
 Unknown 13,329 (19) 3,419 (26) 9,910 (74)
Comorbidity   
 Myocardial infarction 3,769 (5) 943 (25) 2,826 (75)
 Congestive heart failure 6,298 (9) 1,659 (26) 4,639 (74)
 Peripheral vascular disease 5,522 (8) 1,454 (26) 4,068 (74)
 Cerebrovascular disease 12,702 (19) 4,220 (33) 8,482 (67)
 Dementia 6,747 (10) 2,883 (43) 3,864 (57)
 Chronic pulmonary disease 8,674 (13) 2,476 (29) 6,198 (71)
 Connective tissue disease 3,247 (5) 763 (23) 2,484 (77)
 Ulcer disease 3,868 (6) 1,185 (31) 2,683 (69)
 Liver disease 871 (1) 225 (26) 646 (74)
 Diabetes type 1 and 2 6,705 (10) 1,690 (25) 5,015 (75)
 Hemiplegia 175 (< 1) 64 (37) 111 (63)
 Moderate to severe renal disease 2,694 (4) 718 (27) 1,976 (73)
 Cancer 10,974 (16) 2,616 (24) 8,358 (76)
